CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S
12-Aug-2008
"We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology," said Mads Laustsen, CEO of CMC.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.